Universal Plasma Preparation via Erythrocyte Antibody Adsorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing universal plasma depleted of anti-A and anti-B antibodies are costly, time-consuming, and material-intensive, limiting their availability and accessibility, especially since only 4% of the European population has blood group AB, which is universally transfusable.
Innovation Solution
A method involving the combination of blood plasma from groups A, B, or O with erythrocytes from groups A, B, or AB to adsorb anti-A and anti-B antibodies, allowing for the production of universal plasma that can be universally transfused, using a device that facilitates this process in a closed system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If artificially produced antigens or antigen fragments from erythrocytes are used for antibody adsorption, then universal plasma can be produced, but the production becomes expensive and time-consuming
Solution Approach 1:
The patent uses fresh frozen plasma from common blood groups (A, B, or O) as a disposable, cost-effective alternative to expensive artificially produced antigens. The plasma is used once for antibody adsorption and then discarded, eliminating the need for costly reusable antigen production systems while maintaining effective universal plasma production
Solution Approach 2:
The patent introduces erythrocytes as an intermediary substance that facilitates antibody adsorption. Instead of directly using expensive artificial antigens, the method employs readily available erythrocytes from blood groups A, B, or AB as a mediator to bind and remove anti-A and anti-B antibodies from plasma, simplifying the production process
2Adaptability or versatility
If only plasma from blood group AB is used for universal transfusion, then compatibility is ensured, but availability is limited due to low donor frequency
Solution Approach 1:
The patent extracts and removes the problematic anti-A and anti-B antibodies from plasma using erythrocyte adsorption. By taking out these harmful antibodies, plasma from blood groups A, B, and O can be converted into universally compatible plasma, expanding the available supply beyond the limited 4% of AB donors
Solution Approach 2:
The patent makes plasma from multiple blood groups (A, B, and O) universally applicable for transfusion to any recipient by removing their specific antibodies. This multi-functional approach allows a single plasma product to serve all blood types, eliminating the limitation of relying solely on AB plasma donors
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the rapid, simple, and cost-effective production of universal plasma that can be used in any blood donation service, making it universally transfusable and reducing production costs.
Implementation Method 1
combining the blood plasma according to (a) and the erythrocytes according to (b) to obtain a blood plasma depleted in anti-A antibodies and/or anti-B antibodies
Implementation Method 2
combining the blood plasma according to (a) and the erythrocytes according to (b) to obtain a blood plasma depleted in anti-A antibodies and/or anti-B antibodies compared to the blood plasma according to (a), and a cell sediment
Data Source
AI summary
A first aspect of the present invention relates to a method for preparing blood plasma depleted of anti-A antibodies and/or anti-B antibodies. Furthermore, a second aspect of the invention relates to a blood plasma depleted of anti-A antibodies and/or anti-B antibodies that is obtained or obtainable by the method of the first aspect of the invention. A third aspect of the invention relates to the use of a blood plasma depleted of anti-A antibodies and/or anti-B antibodies that is obtained or obtainable by the method of the first aspect of the invention or of a blood plasma depleted of anti-A antibodies and/or anti-B antibodies of the second aspect of the invention. Furthermore, the invention relates to a blood plasma depleted of anti-A antibodies and/or anti-B antibodies or a blood plasma depleted of anti-A antibodies and/or anti-B antibodies of the second aspect of the invention for use in a therapeutic method or an in-vivo diagnostic method or a surgical method. A fourth aspect of the invention relates to a device for preparing blood plasma depleted of anti-A antibodies and/or anti-B antibodies.